An analysis of stromal expression of CD10 in invasive ductal carcinoma of breast and its correlation with histological grade

Thiriveni Balajji G. S., Ulaganathan S., A. Suresh Venkatachalam, K. B. Akila, K. B. Lavanya, S. Vijayalakshmi


Background: Breast cancer is one of the most common cancers among women in India. Stroma has an important role in the pathogenesis of carcinoma of breast. Stromal marker can be novel marker for assessing the prognosis of breast cancer.

Methods: With the representative sections of 30 invasive ductal carcinoma of breast NOS type Hematoxylin and eosin staining was done. Immunohistochemistry was done with CD10. CD10 expression in stroma in cases and control slides were studied and statistically analyzed with histopathological grade.

Results: 46% (14 out of 30) of cases showed strong positivity for stromal CD10. Only two cases of strong positivity for CD10 were noted in the adjacent normal breast parenchyma. Stromal expression of CD10 had a statistically significant association with breast carcinoma than in control slides, p value is 0.002. 77% (10 out of 13) of CD10 positive cases were high grade carcinomas. Association of CD10 expression with high grade tumour was statistically significant (p value is 0.04 which is less than 0.05). No association was found with mean age.

Conclusions: As the grade of breast carcinoma increases the stromal expression of CD10 is increased. Stromal CD10 expression is directly correlated with higher tumour grade. CD10 could be used as novel prognostic marker and used to develop newer drugs.



Epithelial to mesenchymal transition, Grade of breast carcinoma, Stromal CD10, Stromal marker

Full Text:



NCRP, Three year report of population based cancer registries. 2009-2011, ICMR.

Robins and Cotran Pathologic Basis of Disease. 9th ed. volume II. Elsevier; 2015:1051.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.11.

Surakasula A, Nagarjunapu GC, Raghavaiah KV. A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. J Res Pharm Pract. 2014;3:12-8.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade, Modern Pathology. 2007;20:84-9.

Kalof AN, Tam D, Beatty B, Cooper K. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain J Clin Pathol. 2004;57:625-9.

Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of stromal microenvironment in carcinogenesis. Int J Cancer. 2003;107(1):1-10.

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518-27.

Jana SH, Jha BM, Patel C, Jana D, Agarwal A. CD10-A new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Indian J Pathol Microbiol 2014;57:530-6.

Mohammadizadeh F, Salavati M, Afshar Moghaddam N. CD10 expression in stromal component of invasive breast carcinoma: A potential prognostic determinant. J Res Med Sci 2012;17(Spec 2):S194-9.

Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol. 2005;35(5):245-50.

Braham H, Trimeche M, Ziadi S, Mestiri S, Mokni M, Amara K, et al. CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006;449(2):220-4.

Puri V, Jain M, Thomas S. Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67. Int J Breast Cancer. 2011;2011: ID 437957.

Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16:558-64.

Fidler IJ. The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453-8.

Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma; a new predictor of clinical outcome. Virchows Arch. 2002;440:589-93.

Dewar R, Fadare O, Gilmore H, Gown AM. Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med. 2011;135(4):422-9.

Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6:209-17.

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200:429-47.

Curran CS, Keely PJ. Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition. Matrix Biol. 2013;32:95-105.

Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: Correlations with prognostic factors. J Cell Mol Med. 2006;10:499-510.

Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, et al. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010;28:1081-8.

Maguer-Satta V, Besançon R, Bachelard-Cascales E. Concise review: Neutral endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 2011;29:389-96.

Thomas S, Babu RJ, Agarwal K, Puri V, Jain M, et al. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer- A preliminary study. Indian J Cancer. 2013;50:46-51.